Global Precision Medicine Business Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q2 2023 Update

According to the publisher, global precision medicine market size is expected to record a CAGR of 11.3% during 2023-2027 to reach US$126.481 billion by 2027, increasing from US$81.576 billion in 2023. Over the last five years, the sector has recorded a CAGR of 10.4% to reach US$73.909 billion in 2022.

Precision medicine can help identify individuals at higher risk diseases and enable early intervention, as well as guide the development of targeted therapies that have the potential to be more effective and have fewer side effects than traditional treatments. As such, precision medicine has become an important area of research and development in the healthcare industry.

The precision medicine market is currently experiencing significant growth and is expected to continue to grow in the coming years. The market is being driven by factors such as the increasing prevalence of chronic diseases, growing demand for personalized medicine, and technological advancements in genomics and proteomics.

In addition, rising investment in precision medicine research and development is also contributing to market growth. The oncology application segment is expected to hold the largest market share due to the increasing use of precision medicine in cancer treatment.

Big Data Has Become A Powerful Tool In Precision Medicine

• The Journal of Clinical Oncology Clinical Cancer Informatics recently published a study demonstrating that a big data analytics tool capable of mining vast datasets of various types of cancer or cancer-related diseases has the potential to help researchers identify patterns in potential treatment options and greatly accelerate precision medicine. This sophisticated analytics tool was created by researchers at the University of Michigan Rogel Cancer Center, and it amalgamates multiple datasets to transform medical information into meaningful clinical insights.
• Structured data, which is used for statistical analysis, has been deemed the gold standard for cancer research and testing efficacy. To discover cures and various treatment options, cancer researchers depend on “clean data” to produce the required results. On the other hand, unstructured clinical data is more cost-effective to collect than structured data. It is useful for assessing the results of interventions on multiple levels, enabling swift searches, inexpensive storage, and valuable hypothesis generation without requiring to be “clean.”
• Despite some limitations to clinical data aggregation, big data has become a powerful tool in precision medicine. As patient-level genomics play an increasingly vital role in precision medicine, big data analytics continues to amplify its influence in cancer research. Numerous healthcare institutions are paving the way for precision medicine by using big data analytics techniques to develop cause-and-effect models from genomic data based on patient populations.

New Technological Advancements

• Genotype data has been utilised by clinicians as a guide to assist establish the ideal warfarin dose. To assist doctors in maximising pharmacological therapy based on the results of genetic tests, the Clinical Pharmacogenetics Implementation Consortium produced genotype-based drug guidelines.
• Genomic profiling of tumors can inform targeted therapy plans for patients with breast or lung cancer. Precision medicine, integrated into healthcare, has the potential to yield diagnoses that are more precise, predict disease risk before symptoms occur, and design customized treatment plans that maximize safety and efficiency. The trend toward enabling the use of precision medicine by establishing data repositories is not restricted to the United States; examples from Biobanks in many countries, such as the UK Biobank, BioBank Japan, and Australian Genomics Health Alliance demonstrate the power of changing attitudes toward precision medicine on a global scale.
• Although there is much promise for AI and precision medicine, more work still needs to be done to test, validate, and change treatment practices. Researchers face challenges of adopting unified data formats (e.g., Fast Healthcare Interoperability Resources), obtaining sufficient and high quality labeled data for training algorithms, and addressing regulatory, privacy, and sociocultural requirements.

A Glimpse into the Market Dynamics of Precision Medicine

• Invitae, a prominent genetics company, has announced that Blue Shield of California has approved commercial coverage for its Personalized Cancer Monitoring (PCM™) assay, which can identify minimal residual disease (MRD) in patients with solid tumors. This policy, which went into effect on March 1, 2023, deems the test necessary for patients with stage I-IV cancer who have undergone surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or progression.
• Invitae has announced a collaboration with Epic, a healthcare software company renowned for its industry-leading technology. Invitae will be utilizing Aura, Epic's specialized diagnostics suite, to facilitate interactions with provider organizations within the Epic community, thereby providing genetic insights to inform treatment decisions more easily. This collaboration will enable Invitae to streamline the delivery of test result information in providers' usual workflows, thereby making genetic testing more accessible to both patients and providers across the Epic community.
• Precision molecular science biotech Stalicla acquired from Novartis the rights to develop the experimental medication mavoglurant for substance use and neurodevelopmental problems in a multimillion-dollar Swiss agreement. The exclusive, in-licensing arrangement includes secret upfront fees, equity, and up to $270M in marketing and development milestones, as well as further royalties on sales.
• Kaiku Health and Novartis expanded their partnership in 2022 after a successful collaboration. The two companies are together to advance precision medicine.

Research Initiatives

• In recent years, several new initiatives have emerged in addition to ongoing research in genomics. These include IGNITE and CSER-2. The IGNITE program, which stands for 'Implementing GeNomics In Practice', focuses on integrating genomic studies into clinical practice. The program has received funding to support large-scale efforts to incorporate genomic data into electronic tools for more precise patient care. The project involves various models, each with its unique purpose, including establishing a patient's family history, conducting research on genetic markers to prevent diseases, and disseminating information through education.
• The National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), on the other hand, have funded CSER-2. The primary goal of this project is to incorporate genomic sequencing into clinical practice and develop genomic medicines in the best interests of patients. Individuals from all occupations will be exposed to this approach in a healthcare setting.
• CSER-2 has set forth specific goals to implement this concept, including genome sequencing analysis and identification, researching family history, and connecting patients, families, and healthcare professionals to distribute valid information. Additionally, the project aims to overcome barriers to the implementation of such concepts in real-world medical management.

Precision medicine aims to tailor medical treatment to individual patients' needs by understanding the diverse group of patients better. Although various projects and methodologies have been implemented, achieving true precision in healthcare still requires extensive data collection and analysis. The implementation of genomic studies into traditional clinical practice and care has become possible with the new initiatives introduced in the system.

The development of more point care designs is crucial, and data analyzed and studied needs to be fed back into the system to understand any flaws or additions that can be made to the outlay. As the field of precision medicine is vast, conducting ample study plans and research is necessary to fully utilize genomics and gene studies to develop proper-targeted disease predictions and probabilities. To increase the importance and utility of precision medicine, any new information found should be checked, rechecked, collected, studied, and disseminated.

Overall, the precision medicine market has significant growth potential as the healthcare industry continues to prioritize personalized treatment and disease prevention. The study provides a thorough evaluation of the market revenue with quantitative and qualitative intelligence, and forecasts for the market. The report provides a breakdown of the market into both major and niche segments. Additionally, the study assesses the growth and trends of market revenue on a global, regional, and country level from 2,018 to 2027.

This comprehensive report offers an extensive data-driven examination of the emerging prospects within the precision medicine industry. It presents a detailed overview of market size and projections across multiple segments, including category, technology platform, by technology, by gene sequencing technology, by drugs, by route of administration, by application, and by end users. Furthermore, the report includes expert commentary on significant trends, drivers, strategies, innovations, and regulations pertaining to the precision medicine market.

This title provides global and regional insights along with data-centric analysis for the following 5 regions and 20 countries:

• Global
• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• France
• Germany
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• Australia
• India
• South Korea
• Latin America
• Brazil
• Argentina
• Colombia
• MEA
• Israel
• South Africa
• Saudi Arabia
• Turkey

Scope

Insights and data in the report have been segmented under the following six modules:

Module 1: Global Precision Medicine Investment Landscape

This module provides insights and data related to precision medicine partnerships and investment (research and development, mergers and acquisitions, product development, commercialization, licensing, and manufacturing) and allows a peek into the futuristic trends of precision medicine investment area.

Module 2: Global Precision Medicine Clinical Trial Data Assessment

This module evaluates the data available from clinical trials related to precision medicine, representing a bird’s eye view of emerging market dynamics and risks in the diabetes devices & therapeutics sector.

Module 3: Global Precision Medicine Patent Data Analysis

This module presents an exhaustive study of precision medicine patent analytics at various levels, including strategic research planning as well as analyzing their potential applications.

Module 4: Competitive Landscape

This module provides detailed information along with a scoring matrix of key companies related to the precision medicine industry, including their historical performance and the latest developments.

Module 5: Global Precision Medicine Market Size and Forecast

This module provides projections on the market's development during the years 2018-2027 after the profound evaluation of market dynamics at the deeper segmentation level. This report also provides an in-depth, data-centric analysis of the precision medicine market at global, regional and country levels:

Precision medicine market share by category

• Diagnostics
• Therapeutics
• Others

Precision medicine market share by technology platform

• Cloud Based
• On-Premises

Precision medicine market share by technology

• Bioinformatics
• Big Data Analytics
• Drug Discovery
• Companion Diagnostics
• Gene Sequencing
• Others

Precision medicine market share by sequencing technology

• Chain Termination Sequencing
• Nanopore Sequencing
• Sequencing by Ligation
• Pyrosequencing
• Ion Semiconductor Sequencing
• Single Molecule Real Time Sequencing
• Sequencing by Synthesis

Precision medicine market share by drugs

• Mepolizumab
• Osimertinib
• Aripiprazole Lauroxil
• Alectinib
• Others

Precision medicine market share by route of administration

• Injectable
• Oral
• Others

Precision medicine market share by application

• Oncology
• CNS
• Cardiovascular
• Infectious Diseases
• Others

Precision medicine market share by end user

• Pharmaceuticals and Biotechnology Companies
• Diagnostics Companies
• Healthcare IT Specialists/Big Data Companies
• Clinical Laboratories

Precision medicine market share by region

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Germany
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• Australia
• India
• South Korea
• MEA region
• Israel
• South Africa
• Turkey
• Saudi Arabia
• Latin America
• Brazil
• Argentina
• Colombia

Key Companies Covered

• Bayer AG
• BioNTech SE
• CureVac SE
• Personalis, Inc
• F. Hoffmann-La Roche Ltd
• GSK plc
• Immatics Biotechnologies GmbH
• Medtronic
• Moderna, Inc
• NanoString Technologies

Module 6 Regulatory Outlook

This module contains a detailed understanding of the ethical, legal, and social implications of precision medicine industry.

Reasons to buy

• Precision Medicine Market Dynamics: Understand market opportunities and key trends along with forecast (2023-2027). Understand market dynamics across various segments such as by category, technology platform, by technology, by gene sequencing technology, by drugs, by route of administration, by application, and by end users.
• Competitive Landscape Analysis: Market position and snapshot of key players in the development of precision medicine. Each profile includes a brief overview of the company, information on its therapeutic pipeline, financial data (where available), the most recent events, and future direction of the market.
• Clinical Trial Analysis: Insights into opportunities across precision medicine field that have been completed or are still ongoing, using parameters such as trial status, trial registration year, an indication of the target disease, trial phase, patient enrolment, and sponsor/collaborator type.
• Develop Market-Specific Strategies: Identify growth segments based on a thorough analysis of the Precision Medicine patents that have been applied for or granted based on the patent type, the issuing agency, and patent offices involved, the Cooperative Patent Classification (CPC) symbols, the firm type, significant industry and non-industry participants (based on many patents), and discrete patent assignees.
• Financial Deals Insights: Get insights into various precision medicine partnerships that have been developed, including those for research and development (R&D), clinical trials, mergers and acquisitions, product development, commercialization, licencing, and manufacturing. A complete analysis of the various investments made in companies that specialise in developing drugs using precision medicine technologies.